SalioSAM/toxsample11 huggingface dataset:
Poisoning cause: Severe Cannabinoids and Analogs (Pharmaceuticals) toxicity
Management: Treatment is symptomatic and supportive. Administer benzodiazepines for agitation or delirium. Consider diphenhydramine for dystonia or rigidity. SEIZURES: Initially treat with benzodiazepines, add propofol or barbiturates if seizures persist. Airway support as needed. TACHYCARDIA: In agitated patients, tachycardia usually responds to benzodiazepine sedation. Obtain a baseline ECG and institute continuous cardiac monitoring. CHEST PAIN: Myocardial infarction has been reported in adolescents abusing THC homologs. Perform serial ECGs, institute continuous cardiac monitoring and obtain serial troponin concentrations. Treat with aspirin, nitroglycerin and benzodiazepines. HYPERTHERMIA: Perform aggressive cooling measures, such as evaporative or immersive cooling techniques. Severe hyperthermia may require intubation, sedation, and paralysis. ABSTINENCE SYNDROME: Abrupt discontinuation of chronic use can cause profuse sweating, tremors, palpitations, insomnia, headache, depression, diarrhea, nausea, and vomiting. Treat with benzodiazepines. Treat agitation/delirium in patients with suspected exposure to THC homologs with oral or IV benzodiazepines.
Poisoning cause: Mild to Moderate Adderall toxicity
Toxic dose : 6 months - 5 years:	>0.5 mg/kg OR >5 mg,
6 years - 12 years:	>0.5 mg/kg OR >10 mg,
13 years - 64 years:	>0.5 mg/kg OR >20 mg,
65 years - 79 years:	>0.5 mg/kg OR >10 mg,
Management:  Most amphetamine related toxicity may be safely managed with supportive care that includes monitoring airway, breathing, and circulation, and control of agitation with benzodiazepines. Intravenous fluids may be needed for mild dehydration and mild hypotension, and sedation for agitation. Charcoal may be indicated if recent ingestion, airway controlled, and low seizure risk.A) Monitor vital signs (including core temperature) and mental status.
B) Serum concentrations of amphetamine and related agents are not readily available or clinically useful.
C) Urine toxicology screens may detect amphetamines as a class, but do not distinguish between pharmaceutical and illicit forms. False positive amphetamine results may occur after exposure to over-the-counter cold preparations containing ephedrine or pseudoephedrine.
D) No specific lab work is needed in patients with mild clinical signs and symptoms.
E) In patients with severe toxicity, monitor serum electrolytes, CK, renal function, and troponin.
F) Obtain an ECG and institute continuous cardiac monitoring.
G) Consider chest radiograph or CT to exclude pneumothorax or aortic dissection as clinically indicated.
H) Consider a brain CT to exclude traumatic injury or cerebrovascular accident as clinically indicated.
Poisoning cause: Severe Adderall toxicity
Management: Severe agitation requires aggressive treatment to avoid malignant hypertension, rhabdomyolysis, hyperthermia, and seizures. Large doses of benzodiazepines may be needed. Hyperthermia should be aggressively managed with evaporative or immersive cooling measures. Severe hyperthermia may require intubation and paralysis. For tachycardia, treat with intravenous fluids, sedation. Rhabdomyolysis is best treated with adequate 0.9% normal saline; monitor CK, electrolytes, and creatinine. Diuretics and urinary alkalinization are not recommended. Ventricular dysrhythmias should be treated with standard ACLS protocols. Coronary vasospasm can be treated with vasodilators (eg, nitrates and alpha-adrenergic receptor antagonists). Treat severe hypotension with IV 0.9% NaCl at 10 to 20 mL/kg. Add vasopressors (eg, norepinephrine) if unresponsive to fluids.A) Monitor vital signs (including core temperature) and mental status.
B) Serum concentrations of amphetamine and related agents are not readily available or clinically useful.
C) Urine toxicology screens may detect amphetamines as a class, but do not distinguish between pharmaceutical and illicit forms. False positive amphetamine results may occur after exposure to over-the-counter cold preparations containing ephedrine or pseudoephedrine.
D) No specific lab work is needed in patients with mild clinical signs and symptoms.
E) In patients with severe toxicity, monitor serum electrolytes, CK, renal function, and troponin.
F) Obtain an ECG and institute continuous cardiac monitoring.
G) Consider chest radiograph or CT to exclude pneumothorax or aortic dissection as clinically indicated.
H) Consider a brain CT to exclude traumatic injury or cerebrovascular accident as clinically indicated.
Poisoning cause: Mild to Moderate Biktarvy (Bictegravir ) toxicity
Toxic dose : 6 months - 79 years:	>8.5 mg/kg OR >600 mg
Poisoning cause: Severe Biktarvy (Bictegravir ) toxicity
Toxic dose : 6 months - 79 years:	>8.5 mg/kg OR >600 mg
Poisoning cause: Mild to Moderate bumetanide toxicity
Toxic dose : 6 months - 35 months:	>0.014 mg/kg OR >1 mg,
3 years - 12 years:	>0.028 mg/kg OR >2 mg,
13 years - 17 years:	>3 mg,
18 years - 64 years:	>4 mg,
65 years - 79 years:	>2 mg,
Poisoning cause: Severe bumetanide toxicity
Poisoning cause: Mild to Moderate Ropinirole toxicity
Toxic dose : 6 months - 4 years	>1 mg
5 years - 12 years	>4 mg
13 years - 18 years	>8 mg
19 years - 64 years	>12 mg
65 years - 79 years	≥1 mg
Management:  Treatment is symptomatic and supportive.A) Monitor vital signs and ECG in symptomatic patients. 
B) Monitor for CNS depression. 
C) Monitor fluid and electrolyte balance in patients with prolonged vomiting. 
Clinical effect 2: Headache
Clinical effect 3: nasal congestion
Clinical effect 4: dryness of mouth
Clinical effect 5: nausea
Clinical effect 6: vomiting
Clinical effect 7: flushing
Clinical effect 8: coughing
Clinical effect 9: fatigue
Clinical effect 10:  dyskinesia
Clinical effect 11: visual hallucinations
Clinical effect 12: hyperhidrosis
Clinical effect 13: claustrophobia
Clinical effect 14: chorea
Clinical effect 15: palpitations
Clinical effect 16: asthenia
Clinical effect 17: nightmares
Clinical effect 18: orthostatic hypotension
Clinical effect 19: somnolence
Clinical effect 20: confusion
Poisoning cause: Severe Ropinirole toxicity
Management: Treat dyskinesias by decreasing the dose and providing supportive care. Treat dystonia with benzodiazepines and antispasmodic agents (benztropine, diphenhydramine). Treat hypotension with IV fluids and treat dysrhythmias with routine antiarrhythmic agents.
Clinical effect 2: Orthostatic hypotension
Clinical effect 3: Bradycardia
Clinical effect 4: Hypothermia
Clinical effect 5: Supraventricular ectopy
Clinical effect 6: Chest pain
Clinical effect 7: Lethargy
Clinical effect 8: Dizziness
Clinical effect 9: Euphoria
Clinical effect 10: Dyskinesias
Clinical effect 11: Agitation
Clinical effect 12: Confusion
Clinical effect 13: Mydriasis
Clinical effect 14: Drowsiness
Clinical effect 15: Sedation
Clinical effect 16: Vomiting
Clinical effect 17: Nausea
Clinical effect 18: Visual hallucinations
Clinical effect 19: Hyperhidrosis
Clinical effect 20: Claustrophobia
Clinical effect 21: Chorea
Clinical effect 22: Palpitations
Clinical effect 23: Asthenia
Clinical effect 24: Nightmares
Clinical effect 25: Syncope
Clinical effect 26: Somnolence
Clinical effect 27: Involuntary movements
Clinical effect 28: Seizures
Clinical effect 29: Ataxia
Clinical effect 30: Other signs of excessive dopaminergic stimulation
Poisoning cause: Mild to Moderate tacrolimus toxicity
Toxic dose : 6 months - 79 years:	≥0.5 mg/kg OR >50 mg
Management: Treatment is symptomatic and supportive. Monitor vital signs and neurologic status. Monitor fluid status and electrolytes following significant vomiting and/or diarrhea. Administer oral or IV fluids and replace electrolytes as needed. Antidiarrheals may be indicated following persistent symptoms. Seizure activity may develop; treat with IV benzodiazepines, barbiturates. A) Monitor vital signs, including blood pressure. Monitor neurologic status. 
B) Monitor CBC, urinalysis, liver enzymes and kidney function in patients following a significant overdose. 
C) Monitor fluid status in patients that develop significant gastrointestinal symptoms (eg, vomiting, diarrhea). 
D) Monitor serum electrolytes (including potassium, magnesium, glucose) following exposure. 
E) Obtain a baseline ECG, continuous cardiac monitoring and serial ECGs following a significant exposure or as indicated. 
F) Patients receiving these agents are at increased risk for serious infections including bacterial, viral, fungal and protozoal infections including opportunistic infections with therapeutic use. Obtain laboratory studies to determine the presence of infection and monitor for symptoms (ie, fever, chills, flu-like symptoms, etc) as indicated.
Poisoning cause:  Severe tacrolimus toxicity
Management: Treatment is symptomatic and supportive. Monitor CBC with differential and monitor for signs of serious infection (eg, bacterial, viral, fungal, protozoal). Begin anti-infective treatment as soon as possible. Patients may also be at risk to develop anemia and thrombocytopenia. Transfuse packed red blood cells and platelets as indicated. Obtain a baseline ECG in patients (ie, preexisting congestive heart failure, bradyarrhythmias, antiarrhythmic medications) at risk to develop QT prolongation or as indicated. A) Monitor vital signs, including blood pressure. Monitor neurologic status. 
B) Monitor CBC, urinalysis, liver enzymes and kidney function in patients following a significant overdose. 
C) Monitor fluid status in patients that develop significant gastrointestinal symptoms (eg, vomiting, diarrhea). 
D) Monitor serum electrolytes (including potassium, magnesium, glucose) following exposure. 
E) Obtain a baseline ECG, continuous cardiac monitoring and serial ECGs following a significant exposure or as indicated. 
F) Patients receiving these agents are at increased risk for serious infections including bacterial, viral, fungal and protozoal infections including opportunistic infections with therapeutic use. Obtain laboratory studies to determine the presence of infection and monitor for symptoms (ie, fever, chills, flu-like symptoms, etc) as indicated.
Poisoning cause: MILD TO MODERATE amiodarone toxicity
Toxic dose : 6 months - 79 years:	>20 mg/kg OR >2000 mg
Management: Antiemetic medications and IV fluids can be used for gastrointestinal distress. Manage mild hypotension with IV fluids. 
Clinical effect 1: dizziness
Clinical effect 2: nausea
Clinical effect 3: vomiting
Clinical effect 4: bradycardia
Poisoning cause: Severe amiodarone toxicity
Management: Severe toxicity is not expected. If symptomatic bradycardia occurs, administer atropine; if unresponsive, use beta adrenergic agonists (eg, isoproterenol). Consider temporary pacemaker insertion. Treat severe hypotension with IV 0.9% NaCl at 10 to 20 mL/kg. Add vasopressors (eg, norepinephrine) if unresponsive to fluids. Treat patients with torsades de pointes with IV magnesium sulfate; correct electrolyte abnormalities; overdrive pacing may be necessary. 
Clinical effect 2: Bradycardia
Clinical effect 3: heart block
Clinical effect 4: hypotension 
Clinical effect 5: torsades de pointes 
Clinical effect 6: Hepatotoxicity